Table 2.
Clinical factors of the training and validation sets
| Clinical factors | Training set (n = 84) | Validation set (n = 57) | |||
|---|---|---|---|---|---|
| RO (n = 28) | chRCC (n = 56) | P | RO (n = 19) | chRCC (n = 38) | |
| Gender (M/F) | 9/19 | 29/27 | 0.088 | 11/8 | 12/26 |
| Age, year | 58.25 ± 14.22 | 53.02 ± 12.98 | 0.985 | 54.43 ± 16.19 | 55.26 ± 12.75 |
| Laterality (Left/Right) | 11/17 | 35/21 | 0.044 | 6/13 | 21/17 |
| Location (cortical side/medullary side) | 15/13 | 17/39 | 0.039 | 8/11 | 13/25 |
| SEI (present/ absent) | 21/7 | 13/43 | <0.001 | 17/2 | 4/34 |
| Necrosis (present/ absent) | 0/28 | 1/55 | 1.000 | 0/19 | 4/34 |
| Cystic components (present/ absent) | 0/28 | 4/52 | 0.296 | 2/17 | 4/34 |
| Hemorrhage (present/ absent) | 0/28 | 2/54 | 0.550 | 0/19 | 1/37 |
| Calcification (present/ absent) | 0/28 | 7/49 | 0.090 | 1/18 | 2/36 |
| Fat (present/ absent) | 0/28 | 1/55 | 1.000 | 0/19 | 0/38 |
| Perirenal fascia thickening (present/ absent) |
17/11 | 13/43 | <0.001 | 14/5 | 12/26 |
F, female; M, male; RO, renal oncocytoma; SEI, segmental enhancement inversion;chRCC, chromophobe renal cell carcinoma.
P: the p-value of comparison between RO and chRCC in training set; Numerical data are presented as mean ± standard deviation, categorical data as numbers (n).